Sun Pharma Shares to Trade Ex-Date on July 7: Final Dividend of ₹5.50

On July 7, 2025, Sun Pharma shares will trade ex-date, meaning that the shareholders registered in the company’s books will be eligible for the ₹5.50 final dividend.

Sun Pharma Ltd said in an exchange filing, “Recommended a final dividend of Rs. 5.50/- (Rupees Five and Paise Fifty only) per equity share of Re. l/- (Rupee One only) each is recommended to the shareholders for their approval at the ensuing Annual General Meeting of the Company. Monday, 07 July 2025 is fixed as the Record Date for the purpose of determining the Members eligible to receive the final dividend, which, if approved at the Annual General Meeting, shall be paid on or before Friday, 08 August 2025.” 

Also Read: EMI Calculator: Parenting Costs Add Up—1Yr or 2Yr Loan for School Spending?

Sun Pharma Q4FY25 Earnings Highlights 

In FY25, the company delivered strong consolidated financial performance, with gross sales reaching ₹520,412 million, reflecting a robust 9.0% year-on-year growth. India formulation sales led the momentum, rising by 13.7% to ₹169,230 million. In the US market, formulation sales grew by 3.6% to US$1,921 million. Global Specialty business remained a key growth driver, posting an impressive 17.1% increase to US$1,216 million, and contributing 19.7% to total FY25 revenues. Emerging Markets saw a healthy 7.0% growth in formulation sales, totaling US$1,114 million, while the Rest of the World segment recorded a 4.5% rise to US$847 million. 

The company’s operational efficiency further improved, with EBITDA (including other operating revenues) increasing by 17.3% to ₹152,717 million, translating to an EBITDA margin of 29.0%. Adjusted net profit (excluding exceptional items) surged by 19.0% to ₹119,844 million, while reported net profit stood at ₹109,290 million, up from ₹95,764 million in FY24. 

Dilip Shanghvi, Chairman and Managing Director of the Company said, "Our businesses delivered a robust performance for the year, driven by improving market share in India and growth in Global Specialty. The nearterm pipeline in Global Specialty is promising, with products such as Leqselvi and Unloxcyt—the latter through our recently announced Checkpoint acquisition—offering significant improvements in patient care. We look forward to Specialty becoming an increasingly important part of our business."

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.